Want to see PL:CLN full AI Analyst Report?
Celon Pharma SA (CLN) Financial Statements
Celon Pharma SA Financial Overview
Celon Pharma SA's market cap is currently $921.89M. The company's EPS TTM is $2.10; its P/E ratio is 8.14; and it has a dividend yield of 1.90%. Celon Pharma SA is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 209.80M | $ 176.62M | $ 213.92M | $ 161.91M | $ 196.09M |
| Gross Profit | $ -39.48M | $ 113.45M | $ 147.10M | $ 95.45M | $ 134.37M |
| Operating Income | $ -56.76M | $ -36.81M | $ -27.24M | $ -69.76M | $ -10.45M |
| EBITDA | $ -10.48M | $ 14.96M | $ 32.71M | $ 9.32M | $ 27.81M |
| Net Income | $ -79.36M | $ -34.45M | $ -28.12M | $ -39.28M | $ -11.61M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 19.91M | $ 56.52M | $ 114.54M | $ 164.62M | $ 227.55M |
| Total Assets | $ 457.46M | $ 543.79M | $ 569.31M | $ 608.93M | $ 707.14M |
| Total Debt | $ 18.94M | $ 16.93M | $ 25.59M | $ 26.82M | $ 14.92M |
| Net Debt | $ -367.00K | $ 8.65M | $ -6.77M | $ -56.08M | $ -132.88M |
| Total Liabilities | $ 74.47M | $ 98.59M | $ 123.75M | $ 129.29M | $ 153.14M |
| Stockholders' Equity | $ 363.25M | $ 445.21M | $ 445.56M | $ 479.65M | $ 554.00M |
| Cash Flow | |||||
| Free Cash Flow | $ -30.57M | $ -34.13M | $ -41.13M | $ -38.61M | $ 2.60M |
| Operating Cash Flow | $ 23.86M | $ -11.34M | $ -8.31M | $ -4.70M | $ 43.95M |
| Investing Cash Flow | $ -21.64M | $ -7.49M | $ -21.64M | $ -31.47M | $ -121.05M |
| Financing Cash Flow | $ -9.76M | $ 13.32M | $ -20.59M | $ -28.72M | $ 180.91M |
Currency in PLN